{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:16:27Z","timestamp":1780640187285,"version":"3.54.1"},"reference-count":50,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministerio de Econom\u00eda y Competitividad (Instituto de Salud Carlos III)","award":["RD16\/0011\/0012"],"award-info":[{"award-number":["RD16\/0011\/0012"]}]},{"name":"Ministerio de Econom\u00eda y Competitividad (Instituto de Salud Carlos III)","award":["PI18\/0371"],"award-info":[{"award-number":["PI18\/0371"]}]},{"name":"European Regional Development Fund","award":["RD16\/0011\/0012"],"award-info":[{"award-number":["RD16\/0011\/0012"]}]},{"name":"European Regional Development Fund","award":["PI18\/0371"],"award-info":[{"award-number":["PI18\/0371"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>This study aimed to analyze the factors that influence anti-citrullinated protein antibody (ACPA) titers in a seropositive early arthritis (EA) population under non-protocolized treatment with disease-modifying anti-rheumatic drugs (DMARDs). A total of 130 ACPA-positive patients from the PEARL (Princesa Early Arthritis Longitudinal) study were studied along a 5-year follow-up. Sociodemographic, clinical, and therapeutic variables, along with serum samples, were collected at five visits by protocol. Anti-cyclic citrullinated peptide 2 (CCP2) ACPA titers were measured by ELISA. The effect of different variables on anti-CCP2 titers was estimated using longitudinal multivariate analysis models, nested by visit and patient. Data from 471 visits in 130 patients were analyzed. A significant decrease in anti-CCP2 titers was observed at all time-points, compared to baseline, following the decline of disease activity. In the multivariate analysis, active or ever smoking was significantly associated with the highest anti-CCP2 titers while reduction in disease activity was associated with titer decline. After adjusting for these variables, both conventional synthetic (cs) and biologic (b) DMARDs accounted for the decline in anti-CCP2 titers as independent factors. Conclusion: In patients with EA, an early and sustained reduction in ACPA titers can be detected associated with the decline in disease activity, irrespective of the treatment used.<\/jats:p>","DOI":"10.3390\/diagnostics12071773","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T10:36:56Z","timestamp":1658399816000},"page":"1773","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-Citrullinated Protein Antibody Titers Are Independently Modulated by Both Disease Activity and Conventional or Biologic Anti-Rheumatic Drugs"],"prefix":"10.3390","volume":"12","author":[{"given":"Miren","family":"Uriarte Ecenarro","sequence":"first","affiliation":[{"name":"Rheumatology Service, Hospital Universitario La Princesa, IIS-Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1533-6845","authenticated-orcid":false,"given":"Daniel","family":"Useros","sequence":"additional","affiliation":[{"name":"Internal Medicine Service, Hospital Universitario La Princesa, IIS-Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Alfranca","sequence":"additional","affiliation":[{"name":"Immunology Service, Hospital Universitario La Princesa, IIS-Princesa, 28006 Madrid, Spain"},{"name":"Department of Medicine, Faculty of Medicine, Autonomous University of Madrid, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Tejedor","sequence":"additional","affiliation":[{"name":"Immunology Service, Hospital Universitario La Princesa, IIS-Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9614-5199","authenticated-orcid":false,"given":"Isidoro","family":"Gonz\u00e1lez-Alvaro","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Hospital Universitario La Princesa, IIS-Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garc\u00eda-Vicu\u00f1a","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Hospital Universitario La Princesa, IIS-Princesa, 28006 Madrid, Spain"},{"name":"Department of Medicine, Faculty of Medicine, Autonomous University of Madrid, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/ard.62.9.897","article-title":"Rheumatoid arthritis in Spain: Occurrence of extra-articular manifestations and estimates of disease severity","volume":"62","author":"Carmona","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update","volume":"26","author":"Sokka","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","article-title":"What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review","volume":"73","author":"Krabben","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","article-title":"Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search update","volume":"75","author":"Stoffer","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2012-202361","article-title":"Forget personalised medicine and focus on abating disease activity","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/annrheumdis-2018-213700","article-title":"Overdiagnosis and overtreatment in rheumatology: A little caution is in order","volume":"77","author":"Landewe","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","article-title":"The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide","volume":"43","author":"Schellekens","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","article-title":"Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis","volume":"48","author":"Berglin","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/art.22380","article-title":"A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: How to guide individual treatment decisions","volume":"56","author":"Breedveld","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/ard.2005.041376","article-title":"Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset","volume":"65","author":"Berglin","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.62.2.120","article-title":"Anticitrullinated protein\/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage","volume":"62","author":"Meyer","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"R949","DOI":"10.1186\/ar1767","article-title":"Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis","volume":"7","author":"Verpoort","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/ard.2006.068247","article-title":"High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: Results from a 10-year longitudinal study","volume":"67","author":"Syversen","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: Associations, prognostic factors and physiological and radiological characteristics\u2014A large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/art.24390","article-title":"Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis","volume":"61","author":"Paravisini","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/acr.22296","article-title":"Mortality trends in patients with early rheumatoid arthritis over 20 years: Results from the Norfolk Arthritis Register","volume":"66","author":"Humphreys","year":"2014","journal-title":"Arthritis Care Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1136\/annrheumdis-2015-208579","article-title":"Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: A longitudinal study in three European cohorts","volume":"75","author":"Ajeganova","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000009","DOI":"10.1136\/rmdopen-2014-000009","article-title":"Therapeutic implications of autoantibodies in rheumatoid arthritis","volume":"2","author":"Aletaha","year":"2016","journal-title":"RMD Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","article-title":"Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies","volume":"73","author":"Kleyer","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/annrheumdis-2012-202297","article-title":"Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis","volume":"72","author":"Bohler","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/cei.12114","article-title":"The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses","volume":"173","author":"Modi","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"ref_24","first-page":"1972","article-title":"Differential Response of the Rheumatoid Factor and Anticitrullinated Protein Antibodies During Adalimumab Treatment in Patients with Rheumatoid Arthritis","volume":"35","author":"Bos","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e000564","DOI":"10.1136\/rmdopen-2017-000564","article-title":"Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: Post hoc analysis of the AGREE study","volume":"4","author":"Jansen","year":"2018","journal-title":"RMD Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.20659","article-title":"Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody","volume":"50","author":"Mikuls","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00296-016-3506-3","article-title":"Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: A review","volume":"36","author":"Balsa","year":"2016","journal-title":"Rheumatol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/acr.20288","article-title":"Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies","volume":"62","author":"Guzian","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/rheumatology\/keq190","article-title":"Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: A systematic literature review","volume":"50","author":"Barra","year":"2011","journal-title":"Rheumatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3899\/jrheum.120736","article-title":"Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes","volume":"40","author":"Barra","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3899\/jrheum.121313","article-title":"Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: Results from the ESPOIR cohort","volume":"41","author":"Gossec","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ally, M.M., Hodkinson, B., Meyer, P.W., Musenge, E., Tintinger, G.R., Tikly, M., and Anderson, R. (2015). Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. BMC Musculoskelet. Disord., 16.","DOI":"10.1186\/s12891-015-0587-1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13075-019-1815-0","article-title":"In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response","volume":"21","author":"Derksen","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1136\/ard.2004.033571","article-title":"Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: Anti-CP status predicts worse disease activity and greater radiological progression","volume":"64","author":"Wick","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1007\/s00296-011-2260-9","article-title":"The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years","volume":"32","author":"Pereira","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/annrheumdis-2014-205698","article-title":"Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: Results from the SWEFOT trial","volume":"75","author":"Kastbom","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","first-page":"S12","article-title":"Undifferentiated arthritis--disease course assessed in several inception cohorts","volume":"22","author":"Verpoort","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gonzalez-Alvaro, I., Ortiz, A.M., Alvaro-Gracia, J.M., Castaneda, S., Diaz-Sanchez, B., Carvajal, I., Garcia-Vadillo, J.A., Humbria, A., Lopez-Bote, J.P., and Patino, E. (2011). Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0029492"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3899\/jrheum.091333","article-title":"Estimated Cutoff Points for the 28-Joint Disease Activity Score Based on C-reactive Protein in a Longitudinal Register of Early Arthritis","volume":"37","author":"Castrejon","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria","volume":"39","author":"Prevoo","year":"1996","journal-title":"Arthritis Rheum."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-\u00c1lvaro, I., Castrej\u00f3n, I., Ortiz, A.M., Toledano, E., Casta\u00f1eda, S., Garc\u00eda-Vadillo, A., and Carmona, L. (2016). Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161727"},{"key":"ref_44","unstructured":"(2016, April 15). Which DAS-Calculator Do You Wish to Use?. Available online: https:\/\/www.das-score.nl\/das28\/DAScalculators\/dascalculators.html."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.0006-341X.2001.00120.x","article-title":"Akaike\u2019s information criterion in generalized estimating equations","volume":"57","author":"Pan","year":"2001","journal-title":"Biometrics"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40744-021-00404-x","article-title":"Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis","volume":"9","author":"Jabado","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/ard.2010.145268","article-title":"Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes","volume":"70","author":"Bathon","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_49","first-page":"S666","article-title":"The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate","volume":"66","author":"Huizinga","year":"2014","journal-title":"Arthritis Rheum."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/ard.2007.084509","article-title":"Quantifying anti-cyclic citrullinated peptide titres: Clinical utility and association with tobacco exposure in patients with rheumatoid arthritis","volume":"68","author":"Lee","year":"2009","journal-title":"Ann. Rheum. Dis."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/7\/1773\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:55:52Z","timestamp":1760140552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/7\/1773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["diagnostics12071773"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12071773","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]}}}